The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations

Overview

Journal Brain Pathol

Date 2010 Dec 7

PMID 21129061

Citations 66

Authors

Andreas von Deimling

Andrey Korshunov

Christian Hartmann

Affiliations

Soon will be listed here.

Abstract

For some, glioma biomarkers have been expected to solve common diagnostic problems in routine neuropathology service caused by insufficient material, technical shortcomings or lack of experience. Further, biomarkers should predict patient outcome and direct optimal therapy for the individual patient. Unfortunately, current biomarkers still fall somewhat short of these grand expectations. While there has been some progress, it has generally been slow and in small steps. In this review, the newest set of glioma biomarkers: O(6) -methylguanine-DNA methyltransferase (MGMT) methylation, BRAF fusion and IDH1 mutation are discussed. MGMT methylation is well established as a prognostic/predictive marker for glioblastoma; however, technical questions regarding testing remain, it is not currently utilized widely in guiding patient management, and it has proven to be of no assistance in diagnostics. In contrast, BRAF fusion and IDH1 mutation analyses promise to be very helpful for classifying and grading gliomas, while their potential predictive value has yet to be established.

Citing Articles

Predictive and Prognostic Significance of Molecular Biomarkers in Glioblastoma.

Shah S, Nag A, Sachithanandam S, Lucke-Wold B Biomedicines. 2025; 12(12.

PMID: 39767571 PMC: 11727522. DOI: 10.3390/biomedicines12122664.

Noninvasive prediction of CCL2 expression level in high-grade glioma patients.

Zhou Q, Wang Y, Zhang Q, Wei X, Yao Y, Xia L Cancer Med. 2024; 13(14):e70016.

PMID: 39030882 PMC: 11257997. DOI: 10.1002/cam4.70016.

Signaling pathways in brain tumors and therapeutic interventions.

Li S, Wang C, Chen J, Lan Y, Zhang W, Kang Z Signal Transduct Target Ther. 2023; 8(1):8.

PMID: 36596785 PMC: 9810702. DOI: 10.1038/s41392-022-01260-z.

Systematic Investigation of the Diagnostic and Prognostic Impact of LINC01087 in Human Cancers.

De Palma F, Carbonnier V, Salvatore F, Kroemer G, Pol J, Maiuri M Cancers (Basel). 2022; 14(23).

PMID: 36497462 PMC: 9738797. DOI: 10.3390/cancers14235980.

Definition of the Prognostic Role of MGMT Promoter Methylation Value by Pyrosequencing in Newly Diagnosed IDH Wild-Type Glioblastoma Patients Treated with Radiochemotherapy: A Large Multicenter Study.

Caccese M, Simonelli M, Villani V, Rizzato S, Ius T, Pasqualetti F Cancers (Basel). 2022; 14(10).

PMID: 35626029 PMC: 9139569. DOI: 10.3390/cancers14102425.

References

Ward P, Patel J, Wise D, Abdel-Wahab O, Bennett B, Coller H . The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17(3):225-34. PMC: 2849316. DOI: 10.1016/j.ccr.2010.01.020. View

Yan H, Parsons D, Jin G, McLendon R, Rasheed B, Yuan W . IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360(8):765-73. PMC: 2820383. DOI: 10.1056/NEJMoa0808710. View

Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M . Long-term survival with glioblastoma multiforme. Brain. 2007; 130(Pt 10):2596-606. DOI: 10.1093/brain/awm204. View

Rokes C, Remke M, Guha-Thakurta N, Witt O, Korshunov A, Pfister S . Sorafenib plus valproic acid for infant spinal glioblastoma. J Pediatr Hematol Oncol. 2010; 32(6):511-4. DOI: 10.1097/MPH.0b013e3181d74702. View

Criniere E, Kaloshi G, Laigle-Donadey F, Lejeune J, Auger N, Benouaich-Amiel A . MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities. J Neurooncol. 2007; 83(2):173-9. DOI: 10.1007/s11060-006-9320-0. View

Pfister S, Janzarik W, Remke M, Ernst A, Werft W, Becker N . BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008; 118(5):1739-49. PMC: 2289793. DOI: 10.1172/JCI33656. View

Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D . Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2009; 20(1):245-54. PMC: 8094636. DOI: 10.1111/j.1750-3639.2009.00352.x. View

Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A . Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009; 118(4):469-74. DOI: 10.1007/s00401-009-0561-9. View

Jaeckle K, Eyre H, Townsend J, Schulman S, Knudson H, Belanich M . Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 1998; 16(10):3310-5. DOI: 10.1200/JCO.1998.16.10.3310. View

10.

Esteller M, Hamilton S, Burger P, Baylin S, Herman J . Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999; 59(4):793-7. View

11.

Jones D, Kocialkowski S, Liu L, Pearson D, Backlund L, Ichimura K . Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008; 68(21):8673-7. PMC: 2577184. DOI: 10.1158/0008-5472.CAN-08-2097. View

12.

Meyer J, Pusch S, Balss J, Capper D, Mueller W, Christians A . PCR- and restriction endonuclease-based detection of IDH1 mutations. Brain Pathol. 2009; 20(2):298-300. PMC: 8094690. DOI: 10.1111/j.1750-3639.2009.00327.x. View

13.

Felsberg J, Wolter M, Seul H, Friedensdorf B, Goppert M, Sabel M . Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol. 2010; 119(4):501-7. DOI: 10.1007/s00401-010-0647-4. View

14.

Lavon I, Zrihan D, Zelikovitch B, Fellig Y, Fuchs D, Soffer D . Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res. 2007; 13(5):1429-37. DOI: 10.1158/1078-0432.CCR-06-2050. View

15.

Sahm F, Capper D, Meyer J, Hartmann C, Herpel E, Andrulis M . Immunohistochemical analysis of 1844 human epithelial and haematopoietic tumours and sarcomas for IDH1R132H mutation. Histopathology. 2011; 58(7):1167-72. DOI: 10.1111/j.1365-2559.2011.03823.x. View

16.

Jacob K, Albrecht S, Sollier C, Faury D, Sader E, Montpetit A . Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer. 2009; 101(4):722-33. PMC: 2736806. DOI: 10.1038/sj.bjc.6605179. View

17.

Jeuken J, Cornelissen S, Vriezen M, Dekkers M, Errami A, Sijben A . MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest. 2007; 87(10):1055-65. DOI: 10.1038/labinvest.3700664. View

18.

Gross S, Cairns R, Minden M, Driggers E, Bittinger M, Jang H . Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med. 2010; 207(2):339-44. PMC: 2822606. DOI: 10.1084/jem.20092506. View

19.

Gorlia T, van den Bent M, Hegi M, Mirimanoff R, Weller M, Cairncross J . Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2007; 9(1):29-38. DOI: 10.1016/S1470-2045(07)70384-4. View

20.

van den Bent M, Dubbink H, Sanson M, van der Lee-Haarloo C, Hegi M, Jeuken J . MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J Clin Oncol. 2009; 27(35):5881-6. PMC: 2793037. DOI: 10.1200/JCO.2009.24.1034. View